

European Drug Utilization Conference 2025



Bridging
**Data,
Policy &
Patients**
in
Drug
Utilization
Research

**July 01-04
2025**

Uppsala, Sweden



 **ispe** International Society
for Pharmacoepidemiology

 **EuroDURG**

Welcome to EuroDURG Conference 2025

Dear colleagues and friends, on behalf of the Scientific and Local Organising Committees, we are pleased to welcome you to Uppsala and the 2025 EuroDURG Conference: Bridging Data, Policy & Patients in Drug Utilization Research. This meeting offers a rich scientific program which covers a variety of topics addressed through Drug Utilization Research.

These range from important core areas such as adherence, polypharmacy, safety and Drug Utilization Research for specific populations and specific therapeutic areas to policy-related aspects, including accessibility of medicines, medicine shortages and pricing, as well as research in digitalization and artificial intelligence, drugs in the environment and crisis preparedness.

The EuroDURG conference features cross-country research and offers sessions from a global health perspective. Building on previous successful conferences, the conference program provides inspiring keynote talks, interesting presentations, a diversity of posters, interactive workshops and room for an exchange of ideas and knowledge. An accompanying dynamic social program allows participants to meet and discuss with others in the wonderful and vibrant environment of Uppsala.

Björn Wettermark	Sabine Vogler	Indre Treciokiene
Chair	Chair	Co-Chair
Local Organising Committee	Scientific Committee	Scientific Committee

EuroDURG and ISPE



The European Drug Utilization Research Group (EuroDURG) has its roots in the WHO DURG founded in 1976, and it is today a research network of people interested in quality use of medicines from all European countries. The EuroDURG mission is to promote drug utilization research as a means of improving use of drugs by providing an international forum for communication and cooperation between people interested in drug utilization research. Since 2006, EuroDURG constitutes the European chapter of the Special Interest group of Drug Utilization and Health Services Research within ISPE.

The International Society for Pharmacoepidemiology (ISPE) is an international organization dedicated to advancing the health of the public by providing a global forum for the open exchange of scientific information and for the development of policy, education, and advocacy for the field of pharmacoepidemiology, including such areas as pharmacovigilance, drug utilization research, comparative effectiveness review, and therapeutic risk management.

Program & Content

Welcome to EuroDURG 2025	2
Program & Content	3
The Uppsala University Main building	4
Practical information	5
Organising & Scientific committee	5
Program at a glance	6
Tuesday 1 July	8
Wednesday 2 July	10
Thursday 3 July	16
Personal notes	23
Friday 4 July	24
Short Oral Presentations • Book of Abstracts	28
Drug Utilization Research: Methods and Applications • 2nd Edition	29
Social Program	30
Destination Uppsala • Self-guided tour	32
Personal notes	34
Contact, Survey & Sponsors	36

The Uppsala University Main building



Practical information

Wifi for visitors Connect to UU-Guest • Choose Create new account and follow instructions • You will receive an SMS with a login name and password • Choose UU-Guest WiFi again • Log in with your new login name and password • Eduroam is available in the University building.

Cloakroom A staffed cloakroom will be available at the following times:
Tuesday 1 July: 12:00–19:00 • Friday 4 July: 08:30–14:00
Outside of these hours, the cloakroom will remain open but unstaffed.
You are welcome to leave coats and bags, but please do not leave any valuables.

Organising committee

- Björn Wettermark**, Uppsala University (*Chair*)
- Ulf Bergman**, Karolinska Institute
- Elin Dahlén**, NEPI foundation, Uppsala University
- Marie Ekenberg**, Uppsala University
- Mohammadhossein Hajiebrahimi**, Uppsala University
- Mikael Hoffman**, NEPI foundation
- Nataliia Khanyk**, Uppsala University
- Elin Kimland**, Swedish Medical Products Agency
- Marmar Nekoro**, Uppsala University, Swedish Medical Products Agency
- Anders Sundström**, Uppsala Monitoring Centre, Uppsala University
- Johanna Villén**, Uppsala University

Student volunteers

- Hanna Engel • Alice Fors
Prasanna Gunawardana • Johanna Laux
Isabella Mattsson • Sebastian Månsson
Elise Nordenberg • Lucas Sluijs
Olivia Steen • Isabelle Sundell
Albin Tranberg • Ivar Veszelei • Sigrid Welin

Scientific committee

- Sabine Vogler**, Austrian National Public Health Institute (*AT*) (*Chair*)
- Indre Treciokiene**, Vilnius University (*LT*) (*Co-Chair*)
- Ana Tomas Petrovic**, University of Novi Sad (*RS*)
- Carla Torre**, University of Lisbon (*PT*)
- Carlotta Lunghi**, University of Bologna (*IT*)
- Elisabetta Poluzzi**, University of Bologna (*IT*)
- Gabriel Sanf  lix Gimeno**, FISABIO (*ES*)
- Irene Langner**, AOK Research Institute (WIdO) (*DE*)
- Gaye Hafez**, Altinbas University (*TR*)
- Irina Iaru**, University of Medicine and Pharmacy Cluj-Napoca (*RO*)
- Katarina Gvozdanovic**, Teaching Institute of Public Health, Zagreb (*HR*)
- Katja Taxis**, University of Groningen (*NL*)
- Laura Sahm**, University College Cork (*IE*)
- Monique Elseviers**, University of Antwerp (*BE*)
- Ramune Jacobsen**, University of Copenhagen (*DK*)
- Ria Benko**, University of Szeged (*HU*)
- Tanja Mueller**, University of Strathclyde (*GB*)
- Tinne Dilles**, University of Antwerp (*BE*)
- Verica Ivanovska**, WHO and University of Stip (*MK*)
- Sean MacBride Stewart**, NHS Scotland (*GB*)

Program at a glance

Tuesday 1 July 2025

09.00–12.30 Pre-Conference Satellite Program

Three parallel sessions:

- Session I** Real-world data to support regulatory decision-making with methodological examples from the More-EUROPA project
- Session II** Improving drug utilization in practice at the ward (*Uppsala University Hospital*)
- Session III** Strategic challenges in management of cancer and introduction of new cancer medicines (*Uppsala University Hospital*)

14.00–17.45 Educational Sessions (parallel)

- Session I** Introduction to DUR
- Session II** Qualitative/Quantitative mixed methods
- Session III** Measuring medication adherence

15.45–16.15 Coffee break

- Session IV** Critical appraisal of statistics in DUR
- Session V** Longitudinal DU studies
- Session VI** Environment in DUR

16.15–17.45 ENABLE network meeting (by invitation)

18.00 Welcome reception

Wednesday 2 July 2025

09.00–12.30 Scientific Program Part I

Plenary I Informing drug policy decisions in accessibility and equity in medicine use

10.30–11.00 Coffee break

Keynote Lectures (parallel)

- KL I** Adherence (OC I)
- KL II** Crisis preparedness (OC II)
- KL III** Quality use of medicines (OC III)

12.30–13.30 Lunch • “Newcomer” session

13.30–17.45 Scientific Program Part II

Keynote Lectures (parallel)

- KL IV** Evidence generation for the introduction of new drugs using RWD
- KL V** Health literacy and patient engagement

Posters & Short oral communications

15.45–16.15 Coffee break

Workshops (parallel)

- WS I** Cross-national comparisons
- WS II** DUR book: use as research and educational assistant
- WS III** Clinical Decision Support System for drugs

18.00 EuroDURG General Assembly

Program at a glance

Thursday 3 July 2025

09.00–12.30 Scientific Program Part III

Keynote Lectures (parallel)

- KL VI** Accessibility of medicines (OC IV)
- KL VII** Drugs & Environment (OC V)
- KL VIII** Methods in DUR (OC VI)

10.30–11.00 Coffee break

Keynote Lectures (parallel)

- KL IX** Polypharmacy (OC VII)
- KL X** DUR and safety (OC VIII)
- KL XI** DUR in cancer (OC IX)

12.30–13.30 Lunch

13.30–17.45 Scientific Program Part IV

Plenary II AI as aid and challenge in DUR

Posters & Short oral communications

15.45–16.15 Coffee break

Workshops (parallel)

- WS IV** Global environment in DUR: challenges and progress in research in different regions
- WS V** Communication between professionals and the public

19.00 EuroDURG party with dinner

Friday 4 July 2025

09.00–12.30 Scientific Program Part V

Keynote Lectures (parallel)

- KL XII** DUR in psychiatry & pain management (OC X)
- KL XIII** Digitalization and databases in DUR (OC XI)
- KL XIV** DUR in pregnancy and paediatrics (OC XII)

10.30–11.00 Coffee break

Plenary III One Health and DUR

12.30–13.00 Awards & Closings

Legend

- | | |
|-------|------------------------------------|
| ES | Educational session |
| KL | Keynote Lecture |
| OC | Oral communication of abstracts |
| PSOC | Poster & Short oral communications |
| WS | Workshop |
| DU(R) | Drug utilization (research) |
| AI | Artificial intelligence |
| RWD | Real-world data |



Program 1 July

The Uppsala University Main Building was built in the 1880s. At the time, it housed all the University's activities. Since then, the University has grown a lot and today it is spread throughout the city. The Building is still used for lectures, conferences, concerts and university ceremonies. Above the entrance to the Grand Auditorium we read the often-quoted words of the 18th-century philosopher Thomas Thorild: "To think freely is great, but to think rightly is greater."

European Drug Utilization Conference 2025

Tuesday 1 July

09.00–12.30 Pre-Conference Satellite Program (*hall IX and Uppsala University Hospital*)

14.00–14.15 Welcome to Educational sessions (*hall IX*)

Session lead: Björn Wettermark, Uppsala University (*SE*)

14.15–15.45 Educational sessions I, II and III (parallel)

Session I Introduction to DUR (*hall XI*)

Session leads: Indre Treciokiene, Vilnius University (*LT*) • Carlotta Lunghi, University of Bologna (*IT*)

Session II Qualitative/ quantitative mixed methods (*hall IX*)

Session lead: Petra Denig, University Medical Center Groningen (*NL*) • Katja Taxis, University of Groningen (*NL*)

Session III Measuring medication adherence (*hall VIII*)

Session leads: Gabriel Sanfélix-Gimeno, FISABIO (*ES*) • Alexandra Leila Dima, Sant Joan de Déu Research Foundation (*ES*)

15.45–16.15 Coffee break

16.15–17.45 Educational sessions IV, V and VI (parallel)

Session IV Critical appraisal of statistics in DUR (*hall IX*)

Session lead: Morten Andersen, Copenhagen University (*DK*) • Monique Elseviers, University of Antwerp (*BE*)

Session V Longitudinal DU studies (*hall XI*)

Session leads: Elisabetta Poluzzi, University of Bologna (*IT*) • Marie Linder, Karolinska Institute (*SE*)

Session VI Environment in DUR (*hall VIII*)

Session leads: Ana Tomas Petrovic, University of Novi Sad (*RS*) • Johanna Villén, Uppsala University (*SE*) • Lydia Niemi, University of the Highlands and Islands (*UK*)

16.15–17.45 ENABLE network meeting (*by invitation*)

Updates, discussions and presentations from MATEch developers

18.00 Welcome reception (*Faculty rooms*)



Program 2 July

Uppsala University is the oldest Nordic university, founded in 1477. Initially, teaching at the University mainly consisted of lectures in philosophy, law and theology. One of our many world-renowned scientists is Carl von Linné that in 1735 published *Systema Naturae*, an inventory of the three kingdoms of nature: minerals, animals, plants. You can still visit Linnés Botanical garden, which is a popular destination in central Uppsala.

European Drug Utilization Conference 2025

Wednesday 2 July

09.00–12.30 Scientific Program Part I

09.00–10.30 Opening Plenary • Welcome to EuroDURG 2025 (Aula)

Björn Wettermark, Uppsala University (SE), Chair, Local Organising Committee
Elisabetta Poluzzi, University of Bologna (IT), Chair, EuroDURG Executive Committee
Sabine Vogler, Austrian National Public Health Institute (AT), Chair, Scientific Committee
Ann Lindberg, Director General, Swedish Medical Products Agency (SE)
Mary-Beth Ritchey, Rutgers University and CERobs Consulting, President of ISPE (US)

Keynote speakers from the policy field

Equal access to medicines in Europe – a reachable goal or a dream?

Björn Eriksson, Director General, National Board of Health and Welfare (SE)

The role of evidence and data to support policy decisions – examples from OECD practice

Eliana Barrenho, Health Economist, OECD

10.30–11.00 Coffee break

11.00–12.30 Three parallel sessions with a Keynote Lecture & Oral Communications

Session I Adherence (W-KL1/OC1) (hall IV)

This session gives an overview of the European Network to Advance Best practices & technology on medication adherence (ENABLE) achievements and their future goals. Different aspects of adherence research will be discussed by contributors, followed by an open discussion with the audience.

Facilitators

Gabriel Sanfélix-Gimeno, FISABIO (ES)
Alexandra Leila Dima, Sant Joan de Déu Research Foundation (ES)

KEYNOTE LECTURE I

Medication adherence technologies and best practices across European health systems: contributions from the ENABLE network

Alexandra Leila Dima, Sant Joan de Déu Research Foundation (ES)

Wednesday 2 July

Abstracts • Oral presentations:

Maria Rubio-Valera, Institut de Recerca Sant Joan de Déu (ES) • *Improving clinical outcomes through shared decision-making: Findings from the Initial Medication Adherence-cluster randomized controlled trial (IMA-cRCT)*
Fredrik Nyberg, University of Gothenburg (SE) • *The COVID-19 pandemic and statin adherence in Sweden: insights from cohort analyses before and during the crisis*
Nora Wulandari, University of Groningen (NL) • *Factors associated with adherence to glucose-lowering medication among adults with diabetes in Indonesia: A national survey*
Ellen van Loon, University of Groningen (NL) • *The Annual Medication Consultation: Implementation study of an adherence intervention in Dutch community pharmacies*

Session II Crisis preparedness (W-KL2/OC2) (hall IX)

The presentations and discussions of this session will provide answers to: How did crises such as the pandemic or conflicts have affected access to and use of medicines • What lessons have we learnt from these crises that can prepare us for the next one • How can we, through drug utilization research, provide evidence to inform policies and practice to improve access to medicines during crises.

Facilitator

Nataliia Khanyk, Uppsala University (SE)

KEYNOTE LECTURE II

Navigating drug utilization research to improve access to medicines during crises: Lessons from conflict-affected regions
Saleh Aljadeeah, Institute of Tropical Medicine Antwerp (BE)

Abstracts • Oral presentations:

Maarten Lambert, Utrecht University (NL) • *Pharmacists’ Perspectives on Antibiotic Shortages: Implications for Clinical Practice in Australia*
Andrea D. Bertoldi, Federal University of Pelotas (BR) • *Paediatric use of non-evidence-based medications and supplements for COVID-19 treatment or prevention during the pandemic: 2015 Pelotas (Brazil) Birth Cohort Study*
Isabel Hach Paracelsus Medical University Nürnberg (DE) • *Changes in the prevalence of diagnoses and psychotropic drug prescriptions in 12-17 year olds in Germany before and after the COVID-19 pandemic*
Verena Knoll Austrian National Public Health Institute (AT) • *Made in Europe - assessing the feasibility of reshoring active pharmaceutical ingredient production to Europe*

Wednesday 2 July

Session III Quality use of medicines (W-KL3/OC3) (hall X)

This session provides new insights in sustainable medicines use, variation in prescription patterns, with attention for populations with specific needs.

Facilitators

Petra Denig, University Medical Center Groningen (NL)
Elin Dahlen, NEPI – Network for Pharmacoepidemiology & Uppsala University (SE)

KEYNOTE LECTURE III

Quality prescribing - it’s time to get Realistic
Sharon Pfleger, NHS Highland and Robert Gordon University (UK)

Abstracts • Oral presentations:

Hanna Rättö, University of Turku (FI) • *Comparing quality of pharmacotherapy across regions using register data*
Edwin Tan The University of Sydney (AU) • *Quality use of antipsychotics in people with dementia: a national data linkage study*
Juan Carlos Bazo-Alvarez, University College London (UK) • *Prescription Patterns of Antipsychotics in People with Dementia in UK Primary care: Dosage, Duration, and Restart Rates*
Degefaye Zelalem Anlay, Vrije Universiteit Brussel (BE) • *Balancing Palliative Care Needs and Medication Appropriateness: Prevalence and Risk Factors of Initiation and Reinitiation of Medications at the End of Life*

12.30–13.30 Lunch • “Newcomer” session (Meet at the main entrance)

This lunch session offers a unique opportunity to meet with EuroDURG Board members and to learn about EuroDURG, its activities and how to involve.

13.30–17.45 Scientific Program Part II

13.30–14.15 Keynote Lectures IV and V (parallel)

KEYNOTE LECTURE IV • Evidence generation for new drugs (W-KL4) (hall X)

This lecture highlights developments in studies of RWD and its use and showcases potential solutions to address these challenges. A case study with the learnings from the field of heart failure and lung cancer will be presented.

Wednesday 2 July

Facilitators

Björn Wettermark, Uppsala University (SE)
Peter Mol, Medical Center Groningen (NL)

Evidence generation for the introduction of new drugs using RWD
Peter Mol, Medical Center Groningen (NL)
Benedikt Beer, Karolinska Institutet (SE)
Geeske Grit, Dutch Institute for Clinical Auditing (NL)

KEYNOTE LECTURE V • Health literacy and patient engagement (W-KL5) (hall IX)

This lecture offers an introduction to Health Literacy (HL) as a concept and how this relates to DUR. Awareness of the levels of limited HL is crucial to understanding interpreting population level data regarding medication management and use.

Facilitators

Laura Sahm, University College Cork (IE)
Tinne Dilles, University of Antwerp (BE)

Keynote

Medication literacy assessment in geriatric patients
Jenny Gentizon, University of Lausanne (CH)

14.15–15.45 Posters & Short oral communications (halls: page 28)

Welcome to a wealth of knowledge presented in several parallel sessions on all EuroDURG Conference topics.

15.45–16.45 Coffee break

16.45–17.45 Workshops I, II and III (parallel)

Workshop I Cross-national comparisons (hall X)

This workshop starts with two short presentations of CNC studies performed in Latin-America and Europe focusing on the challenges and pitfalls encountered. Attendees will be offered to obtain more insight in the validity of CNC studies. On the hand of a published CNC study and using the recently developed CNC checklist, they will evaluate the quality of the data used and learn to detect possible bias in population and drug coverage that can jeopardize comparison.

Wednesday 2 July

Workshop leads

Monique Elseviers, University of Antwerp (BE)
Ria Benko, University of Szeged (HU)

Keynote

A cross-national study of data sources for DUR in Latin-American countries
Luciane Lopes, University of Sorocaba (BR)

The prevalence of polypharmacy in older Europeans: a multi-national database study of general practitioner prescribing
Marion Bennie, University of Strathclyde (UK)

Workshop II DUR book: use as research and educational assistant (hall IV)

The second edition of the DUR book, published in 2024 with numerous contributions of the EuroDURG community, offers a wealth of information and is a valuable guide for teaching. In this workshop you learn about the outline and purpose of the book and how to use it in education.

Workshop leads

Indre Treciokiene, Vilnius University (LT)
Björn Wettermark, Uppsala University (SE)

Workshop III Clinical Decision Support System for drugs (hall IX)

This workshop informs about the SAPVAL (Systems-Assisted Pharmaceutical VALidation) project undertaken at Uppsala University Hospital with the aim to enhance and deepen the medical aspect of the pharmaceutical assessment.

Workshop lead

Ulrika Gillespie, Uppsala University Hospital (SE)

18.00 EuroDURG General Assembly (hall IX)

Participate in the EuroDURG community & learn about past activities and future plans of EuroDURG.



Program 3 July

Uppsala Cathedral dates to the late 13th century and, at a height of 118.7 metres (389 ft) it is the tallest church in the Nordic countries. This landmark serves as seat of the Archbishop of Uppsala, the primate of Sweden. A number of Swedish monarchs and other notable people were buried inside the cathedral, including Eric the Saint, 16th-century king Gustav Vasa, world-renowned scientist Carl von Linné and Nobel Peace Prize recipient Nathan Söderblom.

Thursday 3 July

09.00–12.30 Scientific Program Part III

09.00–10.30 Three parallel sessions with a Keynote Lecture & Oral Communications

Session I Accessibility of medicines (T-KL6/OC4) (hall X)

The session will address: Understanding the concept of accessibility and learning about existing causes for accessibility issues in Europe • Learning about policy options to address this issue • Highlighting the role of DUR in providing data on this topic and potentially also exploring future role of DUR in this area.

Facilitator

Katarina Gvozdanović, Teaching Institute of Public Health (HR)

KEYNOTE LECTURE VI

Ensuring sustainable and equitable patient access to affordable medicines – Do we need innovation in policy-making?

Sabine Vogler, Austrian National Public Health Institute (AT)

Abstracts • Oral presentations:

Satu Kuusisto, Social Insurance Institution of Finland (Kela) (FI) • *Impact of reimbursement decision on asthma medication use – A nationwide register-based study from Finland*

Haitham Lamin, Uppsala University (SE) • *High-cost protection and pharmaceuticals consumption in Sweden*

Maarten Lambert, Utrecht University (NL) • *Impact of Antibiotic Shortages on Antibiotic Utilisation in the Community: A Cross-National Comparison*

Isabelle Sundell, Uppsala University (SE) • *Attitudes Among Swedish General Practitioners Surrounding the Use of GLP-1 Receptor Agonists for Treating Overweight and Obesity*

Session II Drugs & environment (T-KL7/OC5) (hall IX)

The session addresses how drug utilization studies with environmental perspective can guide policymakers and other stakeholders by identifying the most alarming medicines for specific geographical areas and proposing measures to limit pharmaceutical pollution.

Thursday 3 July

Facilitators

Ana Tomas Petrovic, University of Novi Sad (RS)
Elisabetta Poluzzi, University of Bologna (IT)

KEYNOTE LECTURE VII

The Pharmacy of the fish – Pharmaceuticals in the environment and their environmental impact
Gerd Maack, German Environment Agency (DE)

Abstracts • Oral presentations:

Elisabetta Poluzzi, University of Bologna (IT) • Environmental impact of antidepressants:
is a new prescription framework possible?
Lydia Niemi, University of the Highlands and Islands (UK) • Integration of drug utilisation and environmental data:
Working together towards environmentally informed pharmaceutical prescribing in Scotland
Björn Ericsson, Region Gävleborg (SE) • Promoting sustainable prescribing:
experiences from two Swedish Drug & Therapeutics Committees
Milad Sadreghaemy, Utrecht University (NL) • Patient Preferences Regarding Drug Use and Its Environmental Impact

Session III Methods in DUR (T-KL8/OC6) (hall IV)

The session addresses several aspects around methods in DUR, including: What are challenges in current DUR methods • Which contributions of methodological advances in DUR to the overall evidence base and informed policy-making have been observed • How to increase access to data

Facilitators

Carlotta Lunghi, University of Bologna and Link Campus University (IT)
Anders Sundström, Uppsala Monitoring Centre (SE)

KEYNOTE LECTURE VIII

Record linkage of registries to study utilization and effects of medicines – Experience from the SCIFI-PEARL project
Fredrik Nyberg, Gothenburg University (SE)

Thursday 3 July

Abstracts • Oral presentations:

Robert Vander Stichele, Ghent University (BE) • Linking the ATC classification to the ISO/CEN standardized global Identification of medicinal products and to national identifiers of medicinal product packages. Quality control and refinement of the measurement of exposure to medicines in big data
Angela Boccia, University of Bologna (IT) • Contribution to the Development of the ATC/DDD Classification System from Italian Working Group on DDD: Assigning a Defined Daily Dose (DDD) to Anti-Angiogenic Drugs (ATC S01LA)
Aleksi Hamina, Niuvanniemi Hospital (FI) • Bias stemming from imbalance of incident and prevalent cases in follow-up studies of mortality – something to worry about?
Fabian Windfuhr, University of Groningen (NL) • European perspectives on ethical aspects around utilization of patient registries for medicines decision-making

10.30–11.00 Coffee break

11.00–12.30 Three parallel sessions with a Keynote Lecture & Oral Communications

Session I Polypharmacy (T-KL9/OC7) (hall IV)

The session describes interventions to optimize polypharmacy focusing on older people and address the struggles in evaluation to achieve long term implementation of successful strategies in the context of the vulnerable population of older individuals.

Facilitators

Katja Taxis, University of Groningen (NL)
Ulf Bergman, Karolinska Institutet (SE)

KEYNOTE LECTURE IX

Polypharmacy and deprescribing: when appropriate medication becomes inappropriate
Petra Denig, University Medical Center Groningen (NL)

Thursday 3 July

Abstracts • Oral presentations:

Daniala Weir, Utrecht University (NL) • *Medication Trajectories Among Individuals with Diabetes Type 2 and Other Chronic Conditions: A Descriptive Study*
Ruveyda Yilmaz, OLVG Ziekenhuis (NL) • *Dose-dependent relationships observed for prescribing cascades: a cohort study*
Kieran Dalton, University College Cork (IE) • *Development of a prescribing cascade classification framework: a modified nominal group technique study*
Alessandro Cesare Rosa, Lazio Regional Health Service (IT) • *Identification of the target population for a deprescribing and medication review service in general practice: A pilot project in Italy*

Session II DUR and safety (T-KL10/OC8) (hall X)

This session aims to enhance the fact that DUR is needed for improving real-life medication safety, guiding rational drug use and enabling country benchmarking in terms of quality of prescribing for better public health outcomes.

Facilitators

Katarina Gvozdanović, Teaching Institute of Public Health (HR)
Carla Torre, University of Lisbon (PT)

KEYNOTE LECTURE X

Drug utilisation in pharmacovigilance – a regulatory perspective
Ulla Wändel Liminga, Swedish Medical Products Agency (SE)

Abstracts • Oral presentations:

Iva Kuliš, Agency for Medicinal Products and Medical Devices of Croatia (HALMED) (HR) • *Analysis of JAK inhibitors prescribing trends in Croatia in the view of new risk minimisation measures*
Gabriela Rolová, Charles University (CZ) • *Mortality among patients with long-term prescription opioid use in Norway*
Carlotta Lunghi, University of Bologna (IT) • *Psychotropic Medication Use and Mortality Risk in Cluster B Personality Disorders: A Nested Case-Control Study*
Mohammed Alsuwat, University of Manchester (UK) • *Understanding Medication Safety in Prison Healthcare: A Review of Incident Reports*

Thursday 3 July

Session III DUR in cancer (T-KL11/OC9) (hall IX)

This session addresses the role of DUR in informing evidence-based cancer care, addressing disparities and shaping future policies.

Facilitators

Hossein Hajiebrahimi, Uppsala University (SE)
Amanj Kurdi, University of Strathclyde (UK)

KEYNOTE LECTURE XI

Cancer in Europe 2025 - Disease Burden, Costs and Access to Medicines
Nils Wilking, Karolinska Institute (SE)

Abstracts • Oral presentations:

Sieta T. de Vries, University of Groningen (NL) • *Views of European Union medicine regulators and healthcare professionals on the approved versus prescribed dose of Protein Kinase Inhibitors: An interview study*
Claudia Garcia Serpa Osorio-de-Castro, Escola Nacional de Saúde Pública Sergio Arouca (BR) • *Perceptions of clinical oncologists and hospital pharmacists on shortages of cancer medicines in Brazil, Chile, Colombia and Ecuador: A qualitative study*
Aya Elhusseiny Shaaban, EPI-PHARE, French National Agency for Medicine and Health Product Safety (ANSM) and the French National Health Insurance Center (CNAM) (FR) • *Real-World Use and Survival Outcomes of Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer and Hormone Receptor-Positive/HER2-Negative Breast Cancer: Insights from the French Early Access Program*
Igor Rubinić, Clinical Hospital Center Rijeka (HR) • *Real-world evidence for pembrolizumab in non-small cell lung cancer: a monocentric cohort study*

12.30–13.30 Lunch

13.30–17.45 Scientific Program Part IV

13.30–14.15 Plenary II AI as aid and challenge in DUR (Aula)

This session informs about and discusses the implications of Artificial intelligence (AI) for DUR and DUR-based policy-making, which have been observed and are expected to come in the near future.

Thursday 3 July

Facilitators

Carlotta Lunghi, University of Bologna and Link Campus University (IT)

Björn Wettermark, Uppsala University (SE)

Keynote

AI-assisted pharmacoepi and drug utilisation research: Analytic tool and dialogue partner

Morten Andersen, University Copenhagen (DK)

14.15–15.45 Posters & Short oral communications (*halls: page 28*)

Welcome to a wealth of knowledge presented in several parallel sessions on all EuroDURG Conference topics.

16.45–17.45 Workshops IV and V (parallel)

Workshop IV Global environment in DUR: challenges and progress in research in different regions (hall X)

This session considers, in a comprehensive way, strengths and challenges in DUR for each and all regions, and summarizes expectations for future directions brought by regions. The goal is to find common ground to share and to foster collaboration to overcome limitations and shortcomings.

Workshop leads

Lisa Pont, University of Technology Sydney (AU)

Claudia Garcia Serpa Osorio-de-Castro, Oswaldo Cruz Foundation (BR)

Workshop V Communication between professionals and the public (*hall IX*)

In this workshop we discuss how to select appropriate means, methods, and language when communicating complex matters affecting healthcare to the general public.

Workshop leads

Irene Langner, Wissenschaftliches Institut der AOK (WIdO) (DE)

Tanja Mueller, University of Strathclyde, Glasgow (UK)

Thursday 3 July

Keynote

Communicating evidence and healthcare information to the public

Karen Luetsch, University of Queensland (AU)

19.00 EuroDURG party with dinner

Enjoy a three-course dinner with musical entertainment, dancing and networking in the EuroDURG community at Uppsala Castle.

Personal notes

[illegible]



Program 4 July

Uppsala Biomedical Centre is home to Uppsala University's Faculties of Pharmacy and Medicine and one of northern Europe's largest research centers in pharmacy, biomedicine, chemistry and medicine. In state-of-the-art premises, we can mobilise all the competencies required to develop a drug from laboratory to clinical treatment. Every semester we welcome hundreds of new students to give them the skills needed to shoulder the responsibilities of tomorrow's pharmaceutical experts.

European Drug Utilization Conference 2025

Friday 4 July

09.00–12.30 Scientific Program Part V

09.00–10.30 Three parallel sessions with a Keynote Lecture & Oral Communications

Session I DUR in psychiatry and pain management (F-KL12/OC10) (hall IX)

This session explores critical issues surrounding drug utilization in psychiatry and pain management, focusing on both current challenges and future opportunities for improving clinical practice.

Facilitator

Gaye Hafez, Altinbas University (TR)

KEYNOTE LECTURE XII

Optimizing Drug Utilization in Psychiatry and Pain Management: Current Trends and Future Directions
Verica Ivanovska, WHO and University of Stip (MK)

Abstracts • Oral presentations:

Larus Gudmundsson, University of Iceland (IS) • *Opioids sales, treatment admissions and mortality in Iceland from 1973 to 2023*

Ignacio Aznar-Lou, Fundació Sant Joan de Déu (ES) • *Long-term use of benzodiazepines in Primary Care in Spain: magnitude of the problem and associated factors through a real world data based study*

Estelle Naumburg, Umeå University (SE) • *Association between cardiac events and ADHD-medical therapy in combination with other psychotropic medications in children, adolescents, and young adults*

Faiza Shahid, University Hospital, LMU Munich (DE) • *Risk of insomnia in patients with depressive disorder following initiating SNRIs vs SSRIs: A Population based Cohort Study*

Session II Digitalization and databases in DUR (F-KL13/OC11) (hall X)

The session provides examples of databases, tools, algorithms and methods that support medication and drug utilization research processes.

Facilitators

Sean MacBride Stewart, NHS Greater Glasgow and Clyde (UK)

Irene Langner, Wissenschaftliches Institut der AOK (DE)

Friday 4 July

KEYNOTE LECTURE XIII

From Data to Decisions: Enhancing Medication Safety with AI, Health Data and Interdisciplinary collaboration
Tora Hammar, Linnaeus University (SE)

Abstracts • Oral presentations:

Petra Denig, University of Groningen (NL) • *Development of computerized algorithms to define deprescribing of cardiovascular and diabetes medication*
Pia Vattulainen, Niuvanniemi Hospital (FI) • *Open-source application for estimating treatment episodes: PRE2DUP-R*
Ghinwa Y. Hayek, Quinten Health (FR) • *An AI powered tool to identify & assess fit-for-use registries for real-world evidence*
Ivar Veszelei, Uppsala University (SE) • *Introduction of biopharmaceuticals in Europe: opportunities and challenges to compare drug utilization patterns across countries*

Session III DUR in pregnancy and paediatrics (F-KL14/OC12) (hall IV)

This session explores the complexities of medication use during pregnancy, childhood and adolescence, as well as prevalence, patterns of use, and the implications of drug exposure in these populations.

Facilitator

Tanja Mueller, University of Strathclyde (UK)
Ramune Jacobsen, University of Copenhagen (DK)

KEYNOTE LECTURE XIV

Challenges and opportunities in paediatric drug utilization research
Elin Kimland, Swedish Medical Products Agency (SE)

Abstracts • Oral presentations:

Carole Marxer, University of Basel (CH) • *Exposure to potentially teratogenic medications before and during the first trimester of pregnancy compared to women of childbearing age: A retrospective analysis of Swiss claims data (2015-2021)*
Silvia Segovia Chacón, Karolinska Institute (SE) • *Use of hypnotics before, during & after pregnancy in Sweden 2007-2022*
Rami AL-gueri, University of Copenhagen (DK) • *Beyond Medication: How Danish Adolescents and Young Adults with Mental Conditions Integrate Humanities-Based Approaches in Their Treatment Journeys*
Carlotta Lunghi, University of Bologna (IT) • *Two Decades of ADHD Medication Use Among Children, Adolescents and Young Adults in Quebec, Canada: Prevalence and Patterns*

Friday 4 July

10.30–11.00 Coffee break

11.00–12.30 Plenary III One Health and DUR (Aula)

In this Plenary, two keynote speakers share their knowledge on One Health. Leaving the Conference, participants will be equipped to both broadly and in depth understand the One Health approach and the wide range of current and future health challenges it encompasses. The keynote lecture helps the participants to understand how DUR and One Health are connected. With this, conference participants will understand how they can contribute with their research in preventing, detecting, reducing and managing health threats at the human-animal-ecosystem interface.

Facilitators

Marmar Nekoro, Swedish Medical Products Agency and Uppsala University (SE)
Ana Tomas Petrovic, University of Novi Sad (RS)

Keynotes

One Health and the different interfaces between people, animals, plants and environment
Susanna Sternberg-Lewerin, Swedish University of Agricultural Sciences (SE)

Medicating the environment: impacts of pharmaceutical pollution on fitness-related traits and behaviours in wildlife
Michael Bertram, Swedish University of Agricultural Sciences (SE)

Panel

Sharon Pfleger, NHS Highland and Robert Gordon University (UK)
Ann Lindberg, Swedish Medical Products Agency (SE)
Lisa Pont, University of Technology Sydney (AU)

12.30–13.00 Awards & Closings (Aula)

Ria Benko, University of Szeged (HU)
Sabine Vogler, Austrian National Public Health Institute (AT), *Chair, Scientific committee*
Björn Wettermark, Uppsala University (SE), *Chair, Local Organizing committee*

Digital Posters incl. Short oral communications

All conference posters are digital and QR codes to access the posters are displayed by theme in the university gallery. Short presentations will be organized in parallel sessions on Wednesday and Thursday as presented below. Please look for the thematic roll-ups to find short oral communications allocated by session

Room	Session	Wednesday 2 July	Thursday 3 July
I	14.15	Adherence 1	Adherence 2
	14.45	Safety 1	Safety 4
	15.15	Late breaking 1	Late breaking 2
IV	14.15	DU Pediatrics	DU Old age
	14.45	Quality 1	Quality 2
	15.15	Method 1	Method 2
VIII	14.15	Cross National Comparisons	Big data
	14.45	Therapeutic areas 1	Therapeutic areas 3
	15.15	Environment	Accessibility
IX	14.15	Health policy 1	Health policy 3
	14.45	DU other populations	Patient perspectives
	15.15	Therapeutic areas 2	Polypharmacy 2
X	14.15	Antibacterials	Antidiabetics
	14.45	Health policy 2	Health policy 4
	15.15	Safety 2	Safety 5
XI	14.15	Interventions 1	Interventions 2
	14.45	Polypharmacy 1	Polypharmacy 3
	15.15	Safety 3	Crises

Book of Abstracts

This year, the conference received over 300 abstract submissions. The research topics spanned a broad range of fields, including medicine accessibility, crisis preparedness, patient perspectives and the quality of medicine use.

The Book of Abstracts presents concise summaries of the research projects showcased at the conference. It is available online at the EuroDURG 2025 webpage

You can also access it via the QR code.



Drug Utilization Research: Methods and Applications • 2nd Edition

Drug Utilization Research (DUR) is a discipline which combines aspects of pharmacotherapy, epidemiology, and health services research into an interdisciplinary set of methods for analyzing and assessing the prescribing, dispensing and consumption of medicines. It combines both qualitative and quantitative approaches to facilitate the safe and effective use of pharmaceuticals.

Drug Utilization Research: Methods and Applications provides a comprehensive introduction to this discipline, prepared by an international team of authors with broad experience in numerous fields. Now reorganized and updated to reflect the latest research and global challenges, it is an indispensable resource for understanding the use of pharmaceuticals.


- Readers of the 2nd edition of Drug Utilization Research will find:
- New chapters on methods, including more hands-on guidance on how to plan and conduct different types of drug utilization
 - A section on specific applications in areas such as psychotropics, opioids, cancer drugs, antibacterials, and cardiovascular drugs
 - A new section with case studies illustrating applications of DUR in different continents
 - Detailed treatment of subjects including DUR and health policy, DUR in specific populations, and many more

Drug Utilization Research is ideal for epidemiologists, pharmacists, physicians, nurses and others interested in drug use and its outcomes.

Editors: Monique Elseviers • Björn Wettermark • Tanja Mueller • Ria Benko • Marion Bennie • Katarina Gvozdanovic • Mikael Hoffmann • Irina Iaru • Verica Ivanovska • Sean MacBride-Stewart • Elisabetta Poluzzi • Lisa Pont • Hege Salvesen Blix • Gabriel Sanfelix-Gimeno • Gisbert Selke • Katja Taxis • Ana Tomas Petrovic • Indre Treciokiene • Sabine Vogler



Please scan QR-code to purchase



Wiley-Blackwell | 624 pages
ISBN: 978-1-119-91167-8 e-book
ISBN: 978-1-119-91165-4 print September 2024

Social program **Experience Uppsala**



Welcome reception

When Tuesday 1 July, 18.00

Where University Main building

Treat yourself to the perfect start of your EuroDURG Conference 2025 in the historic faculty rooms of Uppsala University Main Building.

Included in the conference fee, sponsored by Uppsala University and Uppsala Monitoring Centre



Early career Meet and Greet

When Wednesday 2 July, 18.30

Where Katalin And All That Jazz, Roslagsgatan 1

The Swedish Pharmaceutical Society invites you to discuss your career path and expand your professional network with other European early-career scientists.

Free of charge, Registration required, Early registrants get drinks on the house



Botanical Garden Guided Tour

When Wednesday 2 July, 19.00

Where Meet outside the University Hall

Participate in an exploration of Uppsala University's botanical garden with a focus on pharmacognosy and medicinal plants.

Limited number of places, Registration required, Free of charge

From viking snacks to Swedish fika

Uppsala City Guided Tour

When Wednesday 2 July, 19.00

Where Meet outside the University Hall

Explore Uppsala's must-see sights, stroll through charming old quarters, and uncover the fascinating history of one of Europe's oldest university towns.

Limited number of places, Registration required, Free of charge



Party and dinner at Uppsala Castle

When Thursday 3 July, 19.00

Where Uppsala Castle

Enjoy a three-course dinner with musical entertainment, dancing and networking in the EuroDURG community at Uppsala Castle, the location of several major events in the history of Uppsala and Sweden.

Included in the conference fee



Viking Experience Tour & Mead Tasting

When Friday 4 July, 14.30-19.00

Where Meet outside the University Hall

Step into the world of the Vikings during an unforgettable afternoon exploring the legendary landscape of Old Uppsala including mead tasting and viking-inspired snacks such as dried elk (small fee up to €20).

Limited number of places, Registration required




Destination Uppsala



Start your stroll in the **University Grand Auditorium**, an outstanding example of the best in Swedish 19th-century architecture. Since its inauguration in 1877, the auditorium has been home to Swedish male voice choir Orphei Drängar, provided a concert stage where, among many, Led Zeppelin has performed, not to mention the long-standing tradition of Nobel lectures in connection with the annual Nobel laureate visit in Uppsala.



A few steps from the University Building you reach **Gustavianum**, Uppsala University's oldest preserved building. Built in the 1620s, the premises have since undergone a series of restorations, including the 1663 addition of an anatomical theater. Since 1997, Gustavianum has been a public museum that displays and manages the university's magnificent historical collections, including the world famous Augsburg Art Cabinet.



Just south of Gustavianum you enter **Ingmar Bergmans-gatan**. The Swedish master director was born in 1918 at Uppsala University Hospital and spent a large part of his childhood with his grandmother at **Trädgårdsgatan 12**. In 1982 Bergman returned to Uppsala where the neighborhood surrounding the University Building formed the backdrop for his final and four Academy Awards winning film Fanny and Alexander.



Stroll south and you will find the beautiful **City Gardens** with the world's largest artificially frozen ice surface at **Studenternas Arena**. For many years the Swedish national bandy final ("Sweden's Superbowl") was played here. The most famous of Uppsala's athletes is probably Armand "Mondo" Duplantis, regarded as the greatest pole vaulter of all time, who comes home to Uppsala every spring to compete in his annual Mondo Classic.

Self-guided tour of our beautiful city

West of the gardens **Uppsala Castle** rises. Originally constructed in 1549, the castle has been both remodeled and expanded. The castle was the site of the infamous Sture murders and in 1654, the Swedish government announced the abdication of Queen Christina, a moment recreated by Hollywood in the 1933 blockbuster movie starring Greta Garbo. For the record, Tinseltown version doesn't even come close to the beauty of the original.



At the northern foot of the castle hill you will see the **Carolina Rediviva** Library, the oldest and largest university library building in Sweden. Don't miss the exhibition hall showcasing **Carta Marina**, the first map of the Nordic countries to give details and place names, **The Codex Argenteus**, described by Swedish Nobel Prize laureate Selma Lagerlöf as "incomparable", Mozart's handwritten notes and much more.



Behind the library you reach **Uppsala Old Cemetery**, put into use at the end of the 18th century and a popular destination for strolling Uppsala residents. Among the many notable burials at the cemetery are Secretary-general of the United Nations Dag Hammarskjöld, Swedish physician and public speaker Hans Rosling, Hollywood legend Viveca Lindfors and Swedish Poet Gustaf Fröding.



Congratulations, you have earned a stop at **Ofvandahls Hovkonditori**, perhaps the most legendary of Uppsala's many iconic environments. Here at Sysslomansgatan 5, students and locals have met since the 19th century. Among the many celebrities who made Ofvandahls their regular haunt is author August Strindberg who also lived in the building. We hope you enjoyed your walk through our wonderful town.



Personal notes

This image shows a single sheet of white paper with horizontal ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

Personal notes

[illegible]

Welcome to EuroDURG Conference 2025

Welcome to Sweden, Uppsala and the European Drug Utilization Conference 2025. Here you will get new insights into a variety of topics addressed through Drug Utilization Research. You also have the opportunity to experience the sights and city life no one should miss when visiting Uppsala.

We also want to acknowledge all individuals, universities and organisations who have generously contributed their time and expertise in the creation of the EuroDURG Conference 2025. It is your invaluable support that brings us together here today. Our heartfelt gratitude to you all.

We are **here for you**

Whenever you have any questions about the conference, our program or your stay in Uppsala: do not hesitate to contact us. We in the local organising and scientific committees will be happy to help you. We are on site at all conference activities and you can also reach us by email via eurodurg2025@uu.se

Just a minute **Help us improve your experience**

Destination Uppsala is conducting a survey to demonstrate what a meeting contributes to a city in both monetary and intangible values. Scan the code to access the survey that will only take a few minutes to complete. We thank you for your much appreciated help.



Meet our Sponsors **Thank you for generous support**



UPPSALA
UNIVERSITET



AKADEMISKA
SJUKHUSET

